 This randomized controlled trial will evaluate whether the use of pharmacogenetic testing through a Medication Therapy Management MTM program has a beneficial impact on drug therapy problems. More specifically, cytochrome DNA testing, which provides information with regards to participant specific metabolism of medications, will be used in the evaluation of participant medication regimens. The overall aim of the project is to evaluate if the addition of genetic CYP testing to a standardized MTM Program provides increased clinical value. To answer this question, the investigators will look at the drug therapy problems DTPs identified by the genetic test compared to those DTPs discovered without the test. 